For inadequately evidenced therapies like APRV, randomisation within a controlled trial setting is really important.
It is a different indication (APRV used from outset, not resucue therapy) but we be taking part in the RELEASE trial:
https://warwick.ac.uk/fac/sci/med/research/ctu/trials/release/
It is a different indication (APRV used from outset, not resucue therapy) but we be taking part in the RELEASE trial:
https://warwick.ac.uk/fac/sci/med/research/ctu/trials/release/
Comments
Hopefully this will provide some data either way.